Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chuan Song

Showing results (181-190 of 185) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 185 results.
The Lancet Regional Health. Western Pacific|August 7, 2023
Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96Bin Su, Guiju Gao, Min Wang, et al.
Nature Communications|October 31, 2020
Genomic surveillance of COVID-19 cases in BeijingPengcheng Du, Nan Ding, Jiarui Li, et al.
Science China. Life Sciences|June 4, 2021
Distinct durability of IgM/IgG antibody responses in COVID-19 patients with differing severityJunyan Han, Ning Zhang, Danying Chen, et al.
Acta Pharmacologica Sinica|June 7, 2003
Putative hAPN receptor binding sites in SARS_CoV spike proteinXiao-Jing Yu, Cheng Luo, Jian-Cheng Lin, et al.
Cell Reports|January 4, 2022
Two-step fitness selection for intra-host variations in SARS-CoV-2Jiarui Li, Pengcheng Du, Lijiang Yang, et al.
Pageof 19

Showing results (181-190 of 185) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 185 results.
The Lancet Regional Health. Western Pacific|August 7, 2023
Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96Bin Su, Guiju Gao, Min Wang, et al.
Nature Communications|October 31, 2020
Genomic surveillance of COVID-19 cases in BeijingPengcheng Du, Nan Ding, Jiarui Li, et al.
Science China. Life Sciences|June 4, 2021
Distinct durability of IgM/IgG antibody responses in COVID-19 patients with differing severityJunyan Han, Ning Zhang, Danying Chen, et al.
Acta Pharmacologica Sinica|June 7, 2003
Putative hAPN receptor binding sites in SARS_CoV spike proteinXiao-Jing Yu, Cheng Luo, Jian-Cheng Lin, et al.
Cell Reports|January 4, 2022
Two-step fitness selection for intra-host variations in SARS-CoV-2Jiarui Li, Pengcheng Du, Lijiang Yang, et al.
Pageof 19